Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Fruhwald, FM; Rehak, P; Maier, R; Watzinger, N; Wonisch, M; Klein, W.
Austrian survey of treating heart failure--AUSTRIA.
EUR J HEART FAIL. 2004; 6(7): 947-952.
Doi: 10.1016/j.ejheart.2004.02.004
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Fruhwald Friedrich
- Co-Autor*innen der Med Uni Graz
- Maier Robert
- Rehak Peter
- Watzinger Norbert
- Wonisch Manfred
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Treatment of chronic heart failure is based on the results of large clinical trials, which form the basis of treatment guidelines, such as those from the European Society of Cardiology (ESC). The aim of this study was to record treatment-modalities and the implementation of guidelines of chronic heart failure in clinical practice in Austria. METHODS: Overall 96 general physicians, specialists for internal medicine in private practice or in hospital outpatient departments participated in the survey. Physicians were asked to prospectively document 30 consecutive patients with chronic heart failure. RESULTS: 1880 patients were documented. The majority of patients were treated by general physicians (57%). Coronary artery disease was the most frequent aetiology for heart failure (47%). The most frequently used drugs were blockers of the renin-angiotensin-system (RAS-blocker including ACE-inhibitors and angiotensin-receptor-blockers, 78%), diuretics (76%) and beta-blockers (49%). Other drugs like digitalis and spironolactone were used infrequently. Average doses of ACE-inhibitors were approximately 90% of those recommended by the ESC, average doses of beta-blockers were approximately 50% of those recommended. Treatment among the three classes of physicians differed with respect to RAS-blockers and beta-blockers, which were used infrequently by general practitioners. Both groups of drugs were given more frequently to younger patients (<70 years) while digitalis was given more often to elderly patients. CONCLUSIONS: Results from this survey suggest that Austrian physicians treating patients with heart failure use the appropriate drugs in dosages that are suggested by recently published guidelines (ACE-inhibitors and beta-blockers). However, dosages of spironolactone clearly differed from current recommendations.
- Find related publications in this database (using NLM MeSH Indexing)
- Adrenergic beta-Antagonists - therapeutic use
- Aged - therapeutic use
- Aged, 80 and over - therapeutic use
- Angiotensin-Converting Enzyme Inhibitors - therapeutic use
- Austria - epidemiology
- Cardiovascular Agents - administration and dosage
- Chronic Disease - administration and dosage
- Clinical Trials - administration and dosage
- Coronary Arteriosclerosis - complications
- Diuretics - therapeutic use
- Dose-Response Relationship, Drug - therapeutic use
- Female - therapeutic use
- Heart Failure, Congestive - drug therapy
- Humans - drug therapy
- Hypertension - complications
- Male - complications
- Medical Records - complications
- Middle Aged - complications
- Physician's Practice Patterns - statistics and numerical data
- Practice Guidelines - statistics and numerical data
- Prospective Studies - statistics and numerical data
- Research Support, Non-U.S. Gov't - statistics and numerical data
- Find related publications in this database (Keywords)
- chronic heart failure
- treatment
- survey